# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
$25 million funded at close; up to $25 million of additional capital available at the Company's option, based on the achiev...
TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(1.56) per share which missed the analyst consensus estimate...
Companies Reporting Before The Bell • Mach Natural Resources (NYSE:MNR) is projected to report quarterly earnings at $0.92 per...
TriSalus also expects to report cash and cash equivalents balances of approximately $11.8 million as of December 31, 2023. It e...
For the full year 2023, TriSalus expects to report revenue of approximately $18.5 million. This represents growth of approximat...